Systemic therapy with lenvatinib in advanced hepatocellular carcinoma: what to do in the case of a complete radiologic response?

This is the authors' abstract. We don't add key points for this paper.

We observed the efficacy of this treatment in a male patient,59-year-old, with an increasing HCC lesion of 56 mm in thecaudate process and peripheral satellite lesions detected bycomputed tomography (CT) (Fig. 1a), left portal vein tumourthrombosis (PVTT), VP3 according to the Liver Cancer StudyGroup of Japan (Fig. 1b) and alpha-fetoprotein (aFP) = 3415ng/ml. Following a multidisciplinary discussion, the patientstarted systemic therapy with lenvatinib in April 2020 andpresented six months (Fig. 1c) and a year (Fig. 1d) later, inMay 2021, no active tumour or PVTT on the CT scan andpersistent biological complete tumour response (aFP of 3.9 ng/ml). Therefore, in October 2022, the patient was evaluatedfor possible liver transplantation